Drug
Umbralisib clinical trials
Also written TGR-1202 and RP5264.
- studies test it
- 28
- open now
- 0
- in phase 3
- 1
- first study started
- 2013
How studies write it
Studies that test it under each name
Name
Studies by the year they started
28 studies that test it; most in 2016 (4)
| Year | Studies |
|---|---|
| 2013 | 2 |
| 2014 | 3 |
| 2015 | 3 |
| 2016 | 4 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 4 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 12
- Phase 2
- 18
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 17
TG Therapeutics, Inc. (11) · City of Hope Medical Center (2) · Columbia University (2) · National Cancer Institute (NCI) (1) · Jennifer R. Brown, MD, PhD (1) · University of Chicago (1) · Vanderbilt-Ingram Cancer Center (1) · Dana-Farber Cancer Institute (1)
Often tested with
Tested in the same studies.
Ublituximab (12) · Ibrutinib (3) · Acalabrutinib (2) · Lenalidomide (2) · Pembrolizumab (2) · Ruxolitinib (1) · Bendamustine (1) · Obinutuzumab (1)
Studies
Open first, then newest update. How each study uses umbralisib is read from its arms, and is right about nine times in ten.
Testing it · 28
- Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell LymphomaActive, not recruitingPhase 2City of Hope Medical CenterNCT04783415Written as Umbralisib
- Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular LymphomaActive, not recruitingPhase 2National Cancer Institute (NCI)NCT03269669Written as Umbralisib
- TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to HydroxyureaCompletedPhase 1Vanderbilt-Ingram Cancer CenterNCT02493530Written as TGR-1202
- Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone LymphomaTerminatedPhase 2Massachusetts General HospitalNCT03919175Written as Umbralisib
- Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLLActive, not recruitingPhase 2Jennifer R. Brown, MD, PhDNCT04624633Written as Umbralisib
- TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)TerminatedPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT04163718Written as Umbralisib
- Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHLActive, not recruitingPhase 1University of ChicagoNCT03283137Written as TGR-1202
- Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic LeukemiaTerminatedPhase 3TG Therapeutics, Inc.NCT02612311Written as TGR-1202
- A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCLCompletedPhase 1Dana-Farber Cancer InstituteNCT02268851Written as TGR-1202
- Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior TherapyTerminatedPhase 2TG Therapeutics, Inc.NCT02742090Written as Umbralisib
- Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone LymphomaCompletedPhase 2University of Colorado, DenverNCT04508647Written as Umbralisib
- TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaCompletedPhase 2University of NebraskaNCT02874404Written as PI3K-delta Inhibitor TGR-1202
- Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL)TerminatedPhase 1/2University of Alabama at BirminghamNCT04692155Written as Umbralisib
- Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular LymphomaTerminatedPhase 2TG Therapeutics, Inc.NCT03828448Written as Umbralisib
- Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's LymphomaCompletedPhase 2TG Therapeutics, Inc.NCT03364231Written as Umbralisib
- A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304TerminatedPhase 2TG Therapeutics, Inc.NCT02656303Written as Umbralisib
- Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel TherapyTerminatedPhase 2Weill Medical College of Cornell UniversityNCT04149821Written as Umbralisib
- Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular LymphomaWithdrawnPhase 1/2City of Hope Medical CenterNCT05152459Written as Umbralisib
- Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin LymphomaTerminatedPhase 2University of WashingtonNCT03776864Written as Umbralisib
- Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's TransformationCompletedPhase 1TG Therapeutics, Inc.NCT02535286Written as Umbralisib
See all 28 studies that test umbralisib →
Given in every arm · 6 — umbralisib is usual care beside what is tested
- Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell MalignanciesTerminatedPhase 1TG Therapeutics, Inc.NCT03671590Written as Umbralisib
- Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)TerminatedPhase 2/3TG Therapeutics, Inc.NCT03801525Written as Umbralisib
- Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or VenetoclaxTerminatedPhase 2TG Therapeutics, Inc.NCT04016805Written as Umbralisib
- Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHLTerminatedPhase 1/2TG Therapeutics, Inc.NCT03379051Written as Umbralisib
- Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins LymphomaTerminatedPhase 2/3TG Therapeutics, Inc.NCT02793583Written as Umbralisib
- TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid TumorsCompletedPhase 1TG Therapeutics, Inc.NCT02574663Written as TGR-1202
Codes
What other systems call umbralisib · ClinicalTrials.gg INT000901
- MeSH (NLM) C000626319umbralisibOne source NLM
- UNII (FDA) 38073MQB2AUMBRALISIBConfirmed FDA, NLM, Wikidata
- RxNorm 2478439One source FDA
- Wikidata Q27088612umbralisibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C104413UmbralisibOne source FDA
- DrugBank DB14989One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000626319 | umbralisib | One source NLM |
| UNII (FDA) | 38073MQB2A | UMBRALISIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2478439 | — | One source FDA |
| Wikidata | Q27088612 | umbralisib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C104413 | Umbralisib | One source FDA |
| DrugBank | DB14989 | — | One source Wikidata |
Also registered as umbralisib tosylate (UNII FU8XW5V3FS · RxNorm 2478438).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.